ストックスクリーナーアプリを入手
4.04
0.00%
0.00
アフターアワーズ：
4.05
0.010
+0.25%
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
Deep Track Capital, LP Boosts X4 Pharmaceuticals (XFOR) Stake by 26.84% - GuruFocus
Is OPK Worth Buying as Valuation Meets Improving Business Trends? - TradingView
X4 (XFOR) Financial Update: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade) - Seeking Alpha
Layoff Tracker: Kolon TissueGene cuts 37 US staffers after Phase 3 fail - BioSpace
X4 (XFOR) Share-Price Review: Closes 2.09% Lower at $4.21 in the Current Update; Price-Level Context: the Near-Term Reference Band Stretches From $4.00 to $4.42 in Latest TradingChandelier Stop - vinanet.vn
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Study Explores Industry Growth Toward $2.75 Billion - openPR.com
Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals - Stock Titan
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView
4 Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
Deep Track Capital (XFOR) discloses 8.33% X4 Pharmaceuticals stake with capped warrants - Stock Titan
X4 Pharmaceuticals President John Volpone Sells 24,576 Shares to Settle Tax on RSU Award - Kalkine Media
John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock - MarketBeat
X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock - MarketBeat
X4 Pharma chairman Craig R. sells $210,829 in shares - Investing.com
X4 Pharma chairman Craig R. sells $210,829 in shares By Investing.com - Investing.com India
X4 Pharmaceuticals Executive Chairman Adam R. Craig Sells 47,436 Shares to Cover RSU Tax Liability - Kalkine Media
X4 Pharmaceuticals, Inc SEC Filing (Aug 13, 2026) - Stock Titan
Industry Analysts Just Made A Dazzling Upgrade To Their X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Revenue Forecasts - simplywall.st
Earnings Update: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Just Reported And Analysts Are Boosting Their Estimates - webull.com
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why - Yahoo Finance
XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets - marketbeat.com
Equities Analysts Issue Forecasts for XFOR FY2029 Earnings - MarketBeat
X4 Pharmaceuticals Inc (XFOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
X4 Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
X4 Pharmaceuticals: Q2 Earnings Snapshot - Yahoo Finance
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
X4 Pharmaceuticals (NASDAQ: XFOR) wins EU nod, posts $16.2M Q2 loss - Stock Titan
XFOR Q2'26 Earnings: EPS estimate is (0.18) USD - tradingview.com
Form 4 Rocket Pharmaceuticals Inc For: 6 August By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Perceptive Advisors LLC Increases Stake in X4 Pharmaceuticals, Inc. $XFOR - MarketBeat
Form 4 Supernus Pharmaceuticals Inc For: 31 July By Investing.com - Investing.com UK
XFOR|X4 Pharmaceuticals Inc|Price:3.980|Chg%:-0.020 - TradingKey
BlackRock (NYSE: BLK) discloses 5.9% ownership of X4 Pharmaceuticals (XFOR) stock - Stock Titan
Form 4 Processa Pharmaceuticals Inc For: 28 July By Investing.com - Investing.com UK
Form 4 Olema Pharmaceuticals Inc For: 27 July By Investing.com - Investing.com South Africa
X4 Pharmaceuticals Inc (XFOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
X4 Pharmaceuticals Inc (XFOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
X4 Pharmaceuticals Inc (XFOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
X4 Pharmaceuticals Inc (XFOR) Cash Flow - TradingKey
XFOR|X4 Pharmaceuticals Inc|Price:3.930|Chg%:+0.080 - TradingKey
X4 Pharmaceuticals Inc (XFOR) Balance Sheet - TradingKey
X4 Pharmaceuticals Market Sentiment - Benzinga España
X4 Pharmaceuticals Inc (XFOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
X4 Pharmaceuticals, Inc. Revenue Breakdown – FWB:48Q0 - TradingView
XFOR|X4 Pharmaceuticals Inc|Price:4.195|Chg%:-0.105 - TradingKey
X4 Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:XFOR - TradingView
Form 4 Vertex Pharmaceuticals Inc For: 24 July By Investing.com - Investing.com South Africa
X4 Pharmaceuticals Inc (XFOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com - Investing.com South Africa
Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy - Buffalo News
Frontier tech research, news & data - MLQ.ai
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):